tetano
Editor, Senior Moderator
Antiviral Res. 2015 Jun 23. pii: S0166-3542(15)00146-1. doi: 10.1016/j.antiviral.2015.06.015. [Epub ahead of print]
[h=1]Recombinant influenza virus carrying human adenovirus epitopes elicits protective immunity in mice.[/h] Yang P[SUP]1[/SUP], Li T[SUP]2[/SUP], Liu N[SUP]3[/SUP], Gu H[SUP]4[/SUP], Han L[SUP]2[/SUP], Zhang P[SUP]3[/SUP], Li Z[SUP]3[/SUP], Wang Z[SUP]3[/SUP], Zhang S[SUP]5[/SUP], Wang X[SUP]6[/SUP].
[h=3]Author information[/h]
[h=3]Abstract[/h] Human adenoviruses (HAdVs) are known to cause a broad spectrum of diseases in pediatric and adult patients. As this time, there is no specific therapy for HAdV infection. This study used reverse genetics (RG) to successfully rescue a recombinant influenza virus, termed rFLU/HAdV, with the HAdV hexon protein antigenic epitope sequence inserted in the influenza non-structural (NS1) protein gene. rFLU/HAdV morphological characteristics were observed using electron microscopy. Furthermore, BALB/c mice immunized twice intranasally (i.n.) with 10[SUP]4[/SUP] TCID50 or 10[SUP]5[/SUP] TCID50 rFLU/HAdV showed robust humoral, mucosal, and cell-mediated immune responses in vivo. More importantly, these specific immune responses could protect against subsequent wild-type HAdV-3 (BJ809) or HAdV-7 (BJ1026) challenge, showing a significant reduction in viral load and a noticeable alleviation of histopathological changes in the challenged mouse lung in a dose-dependent manner. These findings highlighted that recombinant rFLU/HAdV warrants further investigation as a promising HAdV candidate vaccine and underscored that the immuno-protection should be confirmed in primate models.
Copyright ? 2015. Published by Elsevier B.V.
[h=4]KEYWORDS:[/h] HAdV; Hexon protein epitopes; Influenza virus; Viral vector
PMID: 26112646 [PubMed - as supplied by publisher]
[h=1]Recombinant influenza virus carrying human adenovirus epitopes elicits protective immunity in mice.[/h] Yang P[SUP]1[/SUP], Li T[SUP]2[/SUP], Liu N[SUP]3[/SUP], Gu H[SUP]4[/SUP], Han L[SUP]2[/SUP], Zhang P[SUP]3[/SUP], Li Z[SUP]3[/SUP], Wang Z[SUP]3[/SUP], Zhang S[SUP]5[/SUP], Wang X[SUP]6[/SUP].
[h=3]Author information[/h]
[h=3]Abstract[/h] Human adenoviruses (HAdVs) are known to cause a broad spectrum of diseases in pediatric and adult patients. As this time, there is no specific therapy for HAdV infection. This study used reverse genetics (RG) to successfully rescue a recombinant influenza virus, termed rFLU/HAdV, with the HAdV hexon protein antigenic epitope sequence inserted in the influenza non-structural (NS1) protein gene. rFLU/HAdV morphological characteristics were observed using electron microscopy. Furthermore, BALB/c mice immunized twice intranasally (i.n.) with 10[SUP]4[/SUP] TCID50 or 10[SUP]5[/SUP] TCID50 rFLU/HAdV showed robust humoral, mucosal, and cell-mediated immune responses in vivo. More importantly, these specific immune responses could protect against subsequent wild-type HAdV-3 (BJ809) or HAdV-7 (BJ1026) challenge, showing a significant reduction in viral load and a noticeable alleviation of histopathological changes in the challenged mouse lung in a dose-dependent manner. These findings highlighted that recombinant rFLU/HAdV warrants further investigation as a promising HAdV candidate vaccine and underscored that the immuno-protection should be confirmed in primate models.
Copyright ? 2015. Published by Elsevier B.V.
[h=4]KEYWORDS:[/h] HAdV; Hexon protein epitopes; Influenza virus; Viral vector
PMID: 26112646 [PubMed - as supplied by publisher]